survodutide

INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...

COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...

INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...